Latest posts tagged with #ASH2025 on Bluesky
For Myeloma Action Month., we translated 6 key studies from #ASH2025 into plain language:
https://ow.ly/ttl350YuwxH
Each summary is 2 pages & includes a box of questions to ask your doctor.
Thank you to the International Myeloma Foundation for your work!
#MultipleMyeloma #SmartPatients
Dr. Andrew Lane discusses the improved outcomes of the Tag-Aza-Ven triplet over standard single-agent therapy for aggressive BPDCN at #ASH2025.
sohoinsider.com/meetings-con...
#TreatmentTuesdays
The CAMMA-3 study shows that subcutaneous cevostamab demonstrates manageable safety and meaningful clinical activity in relapsed/refractory myeloma.
Dr. Phoebe Joy Ho, speaking at #ASH2025 presents the results of this phase lb study.
#TreatmentTuesdays
The LINKER-MM4 trial investigates linvoseltamab as a simplified monotherapy option for newly diagnosed myeloma patients
Speaking at #ASH2025 Dr. Xavier Leleu explains the safety & efficacy findings from this new frontline approach
🎬 [REPLAY] Les replays de la Soirée Post-ASH 2025 sont disponibles !
www.youtube.com/playlist?lis...
#ASH #ASH2025 #FSMR #MaladiesRares
📢 The January 2026 EHC Novel #Treatment Review (#NTR) is here! Highlights from #ASH2025, regulatory updates & advances in haemophilia treatment—FVIII mimetics, gene therapy, rebalancing therapies & more. 👏 Thanks to our NTR Working Group! 🔗 buff.ly/q09vsZp
A new multicenter study led by Dr. Akriti Jain sheds light on how blast phase CML is currently treated in the U.S. and which strategies may offer the best outcomes: binaytara.org/cancernews/a...
#LeukemiaResearch #CML #ASH2025 #Hematology #CancerCare #Binaytara
#TreatmentTuesdays
The inMMyCAR study introduces KLN1010, a novel "in vivo" CAR T-cell therapy that targets BCMA without the need for cell collection & manufacturing. Dr. Phoebe Joy Ho, speaking at #ASH2025 shares promising early results.
Learn more
#ASH2025 highlighted transformative data in #leukemia and myeloproliferative neoplasms. Experts from Cleveland Clinic and Fred Hutchinson noted key findings, such as improved survival with combination therapies in blast-phase CML: buff.ly/EK8dJAi
Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25 by @ferdinandusj.bsky.social. From @cancertherapyadv.bsky.social.
https://bit.ly/45HWHVP
#ASH2025 #lymsm
Highlights from #ASH2025
Dr. Charlotte Pawlyn explains the MajesTEC-3 trial. This showed unprecedented benefits when teclistamab combined with daratumumab is used earlier in the myeloma treatment pathway.
https://f.mtr.cool/lijbryefdl
#TreatmentTuesday #Myeloma
New publication📝 Phase II MITHIC-FL2 first results, presented at #ASH2025, show ORR and CR rates were 92% and 82%, respectively, in patients with ND, high-burden FL treated with mosunetuzumab + zanubrutinib.
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
Redoble de tambor... 2 juegos y 12 horas. (9 R.I.P y Fitness Boxing Exercise with Miku)
Favorito de 2025 9 R.I.P 8 horas Horas de juego: Enero 2 Febrero <1 Septiembre 2 Octubre 8
This is low-key embarrassing (also ofc October was the month I played the most, I always pick up 9RIP around that time ausjajd) #Ash2025
At #ASH2025 we interviewed some of the world's leading researchers and clinicians on studies in bispecific antibodies, CAR-T therapy, personalised treatment approaches and more
Each Tuesday, we'll be sharing these expert video explanations of key myeloma research as part of #TreatmentTuesday
A new era in MPN therapy is here. 🚀
Replay now available with Prof. Serge Verstovsek + Prof. @rubenmesamd.bsky.social sharing key updates and what’s next in targeted treatments.
🎥 Watch: www.gmpnsf.org/post/exclusive-video-fro...
#ASH2025 #MPNsm
Missed our session on Post #ASH2025 Updates?
🌐 You can access past webinars on #YouTube and on our website—all organized by topic for easy navigation.
🔗 Youtube: youtube.com/@hemehub?si=...
🔗Visit hemehub.org today to learn more!
#Hematology #BloodDisorders #BoneMarrowFailure #HEMEHUB
🧬 Approval based on two studies presented at ASH 2025, highlighting sonrotoclax’s potential as a foundational therapy across B-cell malignancies.
🔗 Read more: bit.ly/ONCOnews07J-04
#ONCOnews #OncoAlert #OncEd #Hematology #Lymphoma #ASH2025 #Oncology
Top anime Medalist 9 Takopii no Genzai 9 Watashi wo Tabetai, Hitodenashi 8 Kimetsu no Yaiba Movie 1: Mugenjou-hen - Akaza Sairai 9 Taiyou yori mo Mabushii Hoshi 8
Villainess top 2% Workplace top 2% Time travel top 5% Shoujo top 5% Adult cast top 5% Seinen top 8% Sports top 9% Mystery top 9% Romance top 14% Drama top 22%
30 anime 214 episodes 88h11min. That's 3.7 days of non-stop anime.
Top anime Medalist Takopii no Genzai Watashi wo Tabetai, Hitodenashi Taiyou yori mo Mabushii Hoshi Total time watched: 3.7 days Mean score: 7.72 Completed anime: 18 Genre bias: Villainess, Workplace, Time travel. Favourite season: Summer.
Also got my MAL wrapped that is not exactly the same as the anilist one lmao
#Ash2025 #AshWrapped #MALWrapUp2025
Days active 101/365 Most active day Mar 21 Status posts made 1 Messages received 11 List activity 228 Sociability Introverted Degeneracy Mild Resolution 2025 N/A Biggest fan No one yet Top anime: 1. Takopii no Genzai 2. Look back 3.Kimetsu no Yaiba Infinity Castle Movie 5. Hikaru ga Shinda Natsu Anime stats: 157 eps watched (-21 from 2024). 19 completed (-2 from 2024). 5 dropped. 0 paused. 77.50 mean score. Top 77% for anime. Top manga: 1. The Spark In Your Eyes 2. Meisou Senshi Nagata Kabi 3. Emerald Midnight's Lover 4. The Dawn to Come 5. Her Tale of Shim Chong Manga stats: 264 chapter read (+100 from 2024). 15 completed (+3 from 2024). 5 dropped. 0 paused. 72.30 mean score. Top 93% manga. Top 87% of anilist. Hottest Take: User has dropped Only Hope.
#Ash2025 #AshWrapped
Got my anilist wrapped akdsfh (why is there a degeneracy level, help)
Our session on Post #ASH2025 Updates is now available to watch anytime!
➡️ Full session: youtu.be/RuuvGWo28OE?...
🌐You can also access previous sessions directly at hemehub.org and on YouTube!
#Hematology #BloodDisorders #Myeloma #BoneMarrowFailure #Lymphoma #Leukemia #MedicalEducation #HEMEHUB
New publication📝 50-month follow-up results from the phase III ECHO trial, presented at #ASH2025, show ABR improved PFS (72.5 vs 47.8 months) vs PBR in older patients with TN MCL.
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
#FNAIT is a potentially life-threatening condition with a distinct subset of HPA-1a antibodies that can directly activate platelets through FcγRIIa. Presented at #ASH2025, from @rarediseaseadvisor.bsky.social.
https://bit.ly/4b8SlKS
#ASH25
Cancer drugs that work like double agents?
At #ASH2025, bispecific antibodies showed impressive results in aggressive and indolent lymphomas—especially in older, frailer patients.
@neilosterweil.bsky.social explains: medicalnewsinsider.substack.com/p/double-age...
#CancerCare #Immunotherapy
High rates of vulnerability on a geriatric assessment were identified in a cohort of fit patients aged 60 years or older with #AML when measured at baseline, prior to receiving intensive chemotherapy. Presented at #ASH2025.
https://bit.ly/4jiQIMH
#leusm #AMLsm #ASH25
Nurses notice the subtle clues that save lives.
In the upcoming documentary, SICKLE, @Society for Participatory Medicine Board Member Dr. Brenda Merriweather discusses how she assesses patients through their unique body language.
#sicklecellmatters #ASH2025 #SPM #MedSky
#AML highlights from #ASH2025 include results from the AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies. From @cancertherapyadv.bsky.social.
https://bit.ly/3LmS7Fx
#AcuteMyeloidLeukemia #leusm
From #ASH2025 - Phase 3 trial data show a significant improvement in progression-free survival with use of #teclistamab plus #daratumumab for patients with relapsed or refractory #MultipleMyeloma.
👉 buff.ly/7bKRL6f
#OncSky
New data at #ASH2025 show Secure Bio's Copiktra's (duvelisib) consistent efficacy in heavily pretreated PTCL, with strong signal in AITL informing Phase 3 TERZO trial in nTFHL.
#news #interview #lymphoma #clinicaltrials #oncology
New data at #ASH2025 show Secure Bio's Copiktra's (duvelisib) consistent efficacy in heavily pretreated PTCL, with strong signal in AITL informing Phase 3 TERZO trial in nTFHL.
#news #interview #lymphoma #clinicaltrials #oncology
Researchers from UChicago Medicine shared key breakthroughs at #ASH2025, including early-line CAR T-cell use in myeloma, novel leukemia studies, outcomes in blood cancers, real-world monoclonal antibody data, and more.
UChicagoBSD @uchicagomedicine.bsky.social
https://ow.ly/EzRt50XNkMZ
